BDBM224267 3-(6-{[(1r)-1- cyclobutylethyl] amino}-8-[(2r)-4- (cyclopropylcarbonyl)- 2-methylpiperazin-1- yl]-7-[(trans-4- methylcyclohexyl) methyl]-7h-purin-2-yl)- 1,2,4-oxadiazol- 5(4h)-one::US9540377, 17.16

SMILES C[C@@H]1CN(C(=O)C2CC2)CCN1c1nc2nc(-c3noc(=O)[nH]3)nc(N[C@H](C)C3CCC3)c2n1C[C@H]1CC[C@H](C)CC1

InChI Key InChIKey=KWEBARMWWVLUGT-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 224267   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 224267BDBM224267(US9540377, 17.16 | 3-(6-{[(1r)-1- cyclobutylethyl]...)
Affinity DataIC50: 1.22nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent